rs953038635
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The Val9Ala MnSOD polymorphism does not influence ovarian cancer risk or survival.
|
17936883 |
2007 |
rs9375701
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Meta-analyses combining the largest GWA meta-analysis data sets for these cancers totaling 112,349 cases and 116,421 controls of European ancestry, all together and in pairs, identified at P < 10(-8) seven new cross-cancer loci: three associated with susceptibility to all three cancers (rs17041869/2q13/BCL2L11; rs7937840/11q12/INCENP; rs1469713/19p13/GATAD2A), two breast and ovarian cancer risk loci (rs200182588/9q31/SMC2; rs8037137/15q26/RCCD1), and two breast and prostate cancer risk loci (rs5013329/1p34/NSUN4; rs9375701/6q23/L3MBTL3).
|
27432226 |
2016 |
rs9303542
|
|
|
0.700 |
GeneticVariation |
GWASDB |
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.
|
23535730 |
2013 |
rs9303542
|
|
G |
0.700 |
GeneticVariation |
GWASDB |
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.
|
20852632 |
2010 |
rs920778
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The association between the expression of rs920778 and BC, CC, and OC susceptibility was not clear (alleles T/C: OR = 1.28 [95% CI, 0.87-1.89]; in codominant model: CT/CC OR = 1.10, [95% CI, 0.71-1.71], TT/CC OR = 1.29 [95% CI, 0.59-2.80]; dominant model: TC + TT/CC OR = 1.16, [95% CI, 0.73-1.86]; and recessive model: TT/TC + CC OR = 1.43, [95% CI, 0.83-2.47]).
|
30484890 |
2018 |
rs920778
|
|
|
0.020 |
GeneticVariation |
BEFREE |
These findings propose that HOTAIR rs920778 polymorphism influences ovarian cancer susceptibility and prognosis, and further studies are warranted in other populations.
|
27690631 |
2017 |
rs9110
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we determined the distribution of LTF gene polymorphisms (rs1126477, rs1126478, rs2073495, and rs9110) in the Chinese Han population and investigated whether these polymorphisms were associated with increased risk of ovarian carcinoma in the Chinese.
|
21937479 |
2011 |
rs904571820
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A direct sequencing analysis of p53 revealed a p.V173M mutation in exon 5 in both the breast tumor and the ovarian cancer.
|
28662703 |
2017 |
rs886039920
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.
|
17220212 |
2007 |
rs886039920
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The ITGB3 Leu33Pro polymorphism does not modify breast or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers.
|
19876733 |
2010 |
rs879255288
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for breast and/or ovarian cancer.
|
20437199 |
2010 |
rs878854066
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Cumulative risk analysis revealed 3 unfavorable variants that increased significantly the risk of developing ovarian cancer (p.Ile1145 = ABCB1+ p.Asp1853Asn ATM+ p.Ser406Ala ATP7B- OR 7,47; p = 0,002) and significantly modified the progression free survival (PFS) of the patients, and also two favorable genotypes which protected against ovarian cancer (p.Arg952Lys ATP7B+ p.Arg72Pro TP53- OR 0,50; p = 0,008).
|
25591549 |
2015 |
rs878854066
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.
|
21952824 |
2012 |
rs876660754
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A direct sequencing analysis of p53 revealed a p.V173M mutation in exon 5 in both the breast tumor and the ovarian cancer.
|
28662703 |
2017 |
rs876660702
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The BRCA1 G5193A mutation is too rare to contribute significantly to ovarian cancer in Iceland.
|
15571962 |
2004 |
rs876658943
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The association between BRCA2 Arg372His polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) appropriately derived from fixed effects models.
|
26111274 |
2015 |
rs876658657
|
|
|
0.020 |
GeneticVariation |
BEFREE |
These findings indicate that the -93G>A polymorphism in hMLH1 may affect ovarian cancer susceptibility in the Chinese population.
|
26275295 |
2015 |
rs876658657
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Correction: The hMLH1 -93G>A Polymorphism and Risk of Ovarian Cancer in the Chinese Population.
|
31150525 |
2019 |
rs874945
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SNPs rs12826786, rs7958904, and rs874945 did not correlate with an effect on patient susceptibility to BC, CC, and OC.
|
30484890 |
2018 |
rs873330
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We genotyped the p63 (rs873330 [Genbank, refSNP ID] T > C [T: original base, C: mutant base]) and p73 (rs4648551 G > A and rs6695978 G > A) SNPs in ovarian cancers and healthy controls and analyzed the distributions of genotype frequencies to evaluate the association of the genotypes with the risk of ovarian cancer and the clinicopathological characteristics.
|
23095717 |
2012 |
rs869312774
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs869312756
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
rs861539
|
|
|
0.030 |
GeneticVariation |
BEFREE |
In the subgroup analysis according to ethnicity, the results suggested that XRCC3 Thr241Met polymorphism was not associated with the risk of ovarian cancer in Caucasians population.
|
24254304 |
2014 |
rs861539
|
|
|
0.030 |
GeneticVariation |
BEFREE |
No statistically significant associations between XRCC3 rs861539 polymorphisms and ovarian cancer risk were observed in any genetic models.
|
25006581 |
2014 |
rs861539
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The obtained results indicate that XRCC2 Arg188His and XRCC3 Thr241Met polymorphisms may be positively associated with the incidence of ovarian carcinoma in the population of Polish women.
|
26801223 |
2016 |